Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amcipatricin
- Development stage
- Phase 3
- Lead developer
- Kaken Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Amcipatricin is a water-soluble partricin derivative developed for the potential treatment of systemic fungal infections. It shows in vitro inhibitory activity comparable to or better than Amphotericin B against Candida spp., Cryptococcus neoformans, and Aspergillus spp. In preclinical models, it exhibits dose-dependent efficacy on murine pulmonary aspergillosis models. At doses higher than 1.0 mg/kg of body weight, it shows no renal toxicities and tends to provide better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone) and liposomal amphotericin B.
- Other names
- amcipatricin diascorbate
Beyond the preview
Go deeper on amcipatricin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amcipatricin.